Updates in HER2+ mBC

H

ASCO 2021 Comparison of Standard Anti-HER2 Directed Approaches in MBC Between Initially HER2+ Patients and Patients Initially HER2- With Switch to HER2+

By Hans-Christian Kolberg 5 Videos
463 views
June 14, 2021
Comments 0
Login to view comments. Click here to Login
15:07

2021 ASCO Review on AntiHER2 Antibody-Drug Conjugates in BC: DESTINY…

Guy Jerusalem

173 views
09:37

Trastuzumab Deruxtecan for HER2+ MBC With Brain Mets: DESTINY-Breast…

Nicole Williams

664 views
16:11

2021 ASCO Updates: Hunting for HER2 in Solid Tumors

Erika Hamilton

135 views
10:59

Triplet Targeting Combination in HR+/HER2+ BC: Understanding Signali…

University of Colorado Cancer Center

E. Shagisultanova

306 views
22:37

Case Study Discussion on HER2+ MBC: Trastuzumab Deruxtecan in Heavil…

2021 Virtual Best of Breast

P. Anderson, S. Badve, E. Hamilton, R. L. Mahtani

261 views
15:12

Advances in HER2+ BC: Overview of Current Data

2021 Community Oncology Conference

J. O'Shaughnessy

695 views
13:51

Management of HER2+ MBC: Surveying the Data for ADC, TKI, and Novel …

Total Health

T. Traina, L. Carey

506 views
14:57

Colorado University Highlights on BC Research: Inhibiting Tumor Cell…

University of Colorado Cancer Center

H. Ford, J. Richer, T. Lyons

136 views
06:29

Ongoing Therapy Escalation Trials in HER2+ BC: COMPASSHER2 Data, Tre…

Total Health

J. Meisel, H. Soliman

685 views
04:35

HER2+ Breast Cancer: Optimizing Quality of Life

Virginia Kaklamani

460 views